Press Release Headline – Date Published

• Oncology News Burst from FDA: Pembrolizumab – 12/19/18
• Oncology News Burst from FDA: Atezolizumab – 12/7/18
• Oncology News Burst from FDA: Truxima – 11/28/18
• Oncology News Burst from FDA: Venetoclax – 11/23/18
• Oncology News Burst from FDA: Brentuximab Vedotin – 11/20/18
• Oncology News Burst from FDA: Pembrolizumab – 11/13/18
• Next Generation of Cancer Immunotherapy Primed for Introduction at the 33^rd Annual Meeting of the Society for Immunotherapy of Cancer – 11/1/18
• Oncology News Burst from FDA: Pembrolizumab – 10/31/18
• Society for Immunotherapy of Cancer to Host 5-Day, Intensive Educational Program for Early Career Scientists and Clinicians  – 10/19/18
• Society for Immunotherapy of Cancer Announces Co-Sponsored Workshop with U.S. Food and Drug Administration on Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials – 10/12/18
• Society for Immunotherapy of Cancer (SITC) Congratulates 2018 Nobel Laureates, Past SITC Smalley Award Recipients, James P. Allison, PhD, and Tasuku Honjo, MD, PhD – 10/1/18
• Oncology News Burst from FDA: Cemiplimab-rwlc  – 10/1/18
• Society for Immunotherapy of Cancer Partners with Bonnie J. Addario Lung Cancer Foundation to Increase Participation in the Lung Cancer Registry – 9/26/18
• Oncology News Burst from FDA: Moxetumomab Pasudotox-tdfk – 9/13/18
• Society for Immunotherapy of Cancer Launches Convergence Fellowship Awards in New Collaboration with Stand Up To Cancer – 8/24/18
• Oncology News Alert from FDA: Pembrolizumab and Atezolizumab – 8/22/18
• Oncology News Burst from FDA: Pembrolizumab - 8/20/18
• Oncology News Burst from FDA: Nivolumab – 8/20/18
• Oncology News Burst from FDA: Mogamulizumab – 8/8/18
• Society for Immunotherapy of Cancer Publishes First Clinical Immunotherapy Treatment Guidelines for Non-Small Cell Lung Cancer – 7/17/18
• Society for Immunotherapy of Cancer (SITC) Announces 2018 Recipients of Postdoctoral Cancer Immunotherapy Fellowship Awards – 7/12/18
• Oncology News Burst from FDA: Ipilimumab and Nivolumab – 7/11/18
• Journal for ImmunoTherapy of Cancer Receives First Impact Factor – 6/26/18
• Oncology News Burst from FDA: Pembrolizumab – 6/13/18
• Oncology News Burst from FDA: Pembrolizumab – 6/12/18
• The Society for Immunotherapy of Cancer (SITC) Highlights Cancer Immunotherapy during Cancer Immunotherapy Month^TM – 6/1/18
• Society for Immunotherapy of Cancer (SITC) Updates its Clinical Immunotherapy Treatment Guidelines for Cutaneous Melanoma – 5/30/18
• Luminaries in Cancer Immunotherapy to Support Research Opportunities for Early Career Scientists in Chicago Rock Concert – 5/22/18
• The Society for Immunotherapy of Cancer now Accepting Applications for 2018 SITC Sparkathon Program – 5/21/18
  
• Society for Immunotherapy of Cancer (SITC)-Led Study Demonstrating Prognostic Power of “Immunoscore” Published in The Lancet – 5/10/18
• The Society for Immunotherapy of Cancer Highlights Immunotherapy on Melanoma Monday – 5/7/18
• Oncology News Burst from FDA: Tisagenlecleucel – 5/3/18
• The Society for Immunotherapy of Cancer Announces New Partnerships with the Bonnie J. Addario Lung Cancer Foundation, the Cancer Support Community and Fight Colorectal Cancer – 4/24/18
• Oncology News Burst from FDA: Nivolumab and Ipilimumab – 4/16/18
• The Society for Immunotherapy of Cancer Highlights Immunotherapy During Oral, Head and Neck Cancer Awareness Week – 4/10/18
• Leading Researchers in Cancer Immunotherapy and Biosciences to Collaborate in Novel Two-Day Workshops Hosted by the Society for Immunotherapy of Cancer – 4/5/18
• Oncology News Burst from FDA: Blinatumomab – 3/29/18
• Society for Immunotherapy of Cancer Announces 2018 Recipient of the Richard V. Smalley, MD, Memorial Award and Lectureship – 3/22/18
  
• Oncology News Burst from FDA: Brentuximab Vedotin – 3/21/18
• Oncology News Burst from FDA: Durvalumab – 2/16/18
• The Society for Immunotherapy of Cancer Supports Scientific Research in New Collaboration with Stand Up To Cancer – 1/30/18